Actively Recruiting
Effect of Honey For CIN II
Led by Zuyderland Medisch Centrum · Updated on 2025-06-18
60
Participants Needed
2
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The following hypothesis is tested: Medical grade honey in CIN II causes a higher clearance of the hr-HPV virus and an increase in the normalization of CIN II lesions compared to expectant management.
CONDITIONS
Official Title
Effect of Honey For CIN II
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women aged 18 to 40 years
- Primary CIN II confirmed by biopsy during colposcopic examination
- Sufficient mastery of the Dutch language
You will not qualify if you...
- Presence of abnormal columnar epithelial cells (AIS)
- Negative cytology for high risk HPV
- Use of immunosuppressants or autoimmune diseases such as HIV or CVID
- History of cervical cancer or previous treatment for CIN (LLETZ or imiquimod)
- Pregnancy or intention to become pregnant during the study period
- Legal incompetence
- Known allergies to honey
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Zuyderland MC
Heerlen, Limburg, Netherlands, 6149 PC
Actively Recruiting
2
Maastricht University Medical Centre+
Maastricht, Limburg, Netherlands, 6229 HX
Not Yet Recruiting
Research Team
J
Jordy Mongula, dr.
CONTACT
J
Jasmijn Prop, Drs.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here